EUCTR2013-004595-35-NL进行中（未招募）1 期
Multi-center, randomized, double-blind, placebo-controlled phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult deltaF508 homozygous Cystic Fibrosis patients - Early signs of efficacy study with BAY63-2521 in adult homozygous deltaF508 Cystic Fibrosis patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed informed consent available before any study specific tests or procedures are performed
- •- Patients must be at least 18 years of age at time of inclusion (i.e. upon signature of informed consent)
- •- Patient diagnosed with Cystic Fibrosis according to standard criteria (i.e. either elevated sweat chloride content above 60 mmol/ L and/ or genetic testing)
- •- Patient is homozygous for the deltaF508 mutation
- •- Patient has a mild-to-moderate stage of lung disease as determined by FEV1 (FEV1 between 60 and 90% predicted)
- •- Patient has a stable condition of lung disease (no ongoing or recent pulmonary exacerbation and no change in current treatment) within the last 4 weeks prior to screening
- •- Ability and willingness to understand and follow study procedures for the entire study
- •- Patients do not smoke. Patients with a history of smoking can be included, if they have refrained from smoking for the last 3 months. If a patients starts smoking during the study participation, he/ she needs to be excluded and considered to be a drop out
- •- Body mass index (BMI): = 16 and = 32 kg/ m²
- •- Women of childbearing potential must agree to use adequate contraception when sexually active. ‘Adequate contraception’ is defined as one highly effective form of contraception (intrauterine devices [IUD], contraceptive implants or tubal sterilization) or a combination of methods (hormone method with a barrier method or two barrier methods). If a partner’s vasectomy is the chosen method of contraception or if a partner has documented azoospermia, a hormone or barrier method must be used in combination. Adequate contraception is required from the signing of the informed consent form up until 4 weeks after the last study drug administration.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •- Patients with Cystic Fibrosis with any background other than homozygous deltaF508 mutation
- •- Patients receiving treatment with Ivacaftor
- •- Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization. Also any history of moderate hemoptysis within the 3 months prior to inclusion
- •- Any history of pneumothorax, bronchial artery embolization or massive hemoptysis. Massive hemoptysis being defined as acute bleeding >240 mL in a 24-hour period or recurrent bleeding >100 mL/ d over several days
- •- A positive sputum culture for Burkholderia cenocepacia, Burkholderia dolosa, and/ or Mycobacterium absessus either currently or within the previous year.
- •- Active allergic broncho-pulmonary aspergillosis
- •- Current pulmonary exacerbation
- •- Known history of solid organ transplantation
- •- Known history of any form of pulmonary arterial hypertension
- •- Nasal conditions that would interfere with conducting NPD. Well controlled seasonal allergic rhinitis is not an exclusion criterion.
- •- Known or suspected malignant tumors or a history of malignant tumors
- •- Unstable liver disease as indicated by
- •a.bilirubin >2 times upper limit normal (ULN) and/ or hepatic transaminases >5 times ULN
- •b.signs of severe hepatic insufficiency (e.g. impaired albumin synthesis with an albumin < 32g/ L, hepatic encephalopathy > Grade 1a)
- •- Patients with severe hepatic impairment (Child Pugh C) should be excluded
- •- Recent evidence (within 12 months prior to inclusion) of distal intestinal obstruction syndrome.
- •- Patients with creatinine clearance <15 mL/ min or on dialysis need to be excluded.
- •- Known history of cardiovascular disease unless stable and without therapy changes in the previous 3 months
- •- Known history of clinically relevant arterial hypotension or clinically relevant orthostatic reactions (e.g. as indicated by syncopes, dizziness)
- •- Venous/ arterial thromboembolic diseases (particularly deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction)
- •- Known current thyroid disorders which require treatment (patients with an euthyroid struma who do not need any treatment can participate)
- •- Known hypersensitivity to the study medication (active substances or excipients of the preparations)
- •- Documented severe or clinically significant allergic reactions including anaphylaxis or hives
- •- Intolerance to lactose requiring strictly lactose-free diet and restriction to lactose-free oral medicines (hereditary galactose intolerance, galactose-glucose malabsorption, lactase deficiency)
- •- Recent history (i.e. in the last 12 months prior to screening) of severe hypoglycemic events in patients with severe Cystic Fibrosis diabetes
- •- Any medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator
- •- Smoking (former smokers who have stopped smoking at least 3 months prior to the first screening visit may be included)
- •- Suspicion of drug or alcohol abuse or recent (i.e. within 2 years) history of drug, medicine or alcohol abuse
- •- Donation of blood or plasmapheresis after or within 4 weeks of signing the informed consent form
- •- Concomitant use of the following medication: nitrates or nitric oxide donors (such as amyl nitrite) in any form, PDE 5 inhibitors (such as sildenafil, tadalafil, vardenafil), strong multi pathway CYP and p-gp/ BCRP inhibitors such as azole antimycotics
研究者
相似试验
已完成
2 期
A clinical trial to study the effects of Bacillus subtilis strain PB6, as add-on to standard maintenance therapy in the treatment of mild to moderate ulcerative colitisCTRI/2009/091/000693Kemin Pharmaa division of Kemin Industries South Asia Pvt. Ltd.The Trapezium, No 39, Nelson Manickam Road, Chennai-600029, India
进行中（未招募）
不适用
Multi-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety and efficacy of Bimosiamose 5% Cream for the treatment of patients with chronic plaque type psoriasis - Psoriasis POCchronic plaque-type psoriasis (psoriasis vulgaris)MedDRA version: 9.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisEUCTR2008-000197-20-DERevotar Biopharmaceuticals AG
已完成
2 期
Multi-center, randomized, double-blind, placebo-controlled phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered BAY63-2521 in adult deltaF508 homozygous Cystic Fibrosis patientsmucoviscidosis1002766410010613NL-OMON42435Bayer HealthCare AG5
进行中（未招募）
不适用
Multi-center, randomized, double-blind, placebo-controlled, cross-over Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-017257-35-DERevotar Biopharmaceuticals AG77
已完成
2 期
A placebo controlled clinical trial to evaluate safety and efficacy of two doses of AM 3301 for add-on treatment of mild to moderate active ulcerative colotisCTRI/2010/091/000444Kemin Pharma180